Inovio Pharmaceuticals (INO) Financials

Inovio Pharmaceuticals (NASDAQ: INO) continues to operate as a development-stage biotech with no meaningful product revenue, persistent operating losses, and a balance sheet that has improved in terms of cash but remains highly dependent on external financing.

For the most recent quarter, Q1 2026, Inovio reported no revenue and a net loss of $19.7 million, or $(0.28) per share. Operating expenses totaled $22.0 million, led by $14.1 million in R&D and $7.9 million in SG&A. That was enough to keep the company deeply unprofitable despite some non-operating income.

The most important trend over the last four years is that Inovio has not yet established a recurring revenue stream. Quarterly revenue has been minimal or zero in most periods, with only small amounts recorded in some quarters. That means the investment case still hinges on pipeline progress rather than current sales.

• Cash and investments remain substantial. As of Q1 2026, Inovio held about $26.3 million in cash and equivalents plus $11.4 million in short-term investments, giving it near-term liquidity support.
• Operating cash burn improved versus the prior quarter. Q1 2026 operating cash outflow was $(21.6 million), slightly better than $(19.4 million) in Q4 2025 and far better than some earlier periods that also ran deep losses.
• Investing activity added cash in Q1 2026. The company generated $2.6 million from investing activities, helped by sales/maturities of investments exceeding new purchases.
• Equity issuance still provided financing support. In Q1 2026, Inovio raised about $1.1 million from common stock issuance, extending its runway.
• Losses remain large but less severe than some prior quarters. Q1 2026 net loss of $19.7 million improved from $45.5 million in Q3 2025 and $23.5 million in Q2 2025.
• Other income can swing results materially. In several quarters, investment income and other non-operating items significantly affected pre-tax results, creating volatility in reported earnings.
• Share count has risen over time. Weighted average basic shares increased from roughly 23.3 million in Q1 2024 to 69.1 million in Q1 2026, which dilutes future per-share recovery.
• Revenue remains essentially nonexistent. Q1 2026 reported $0 in revenue, and most of the historical quarters shown also had no meaningful operating revenue.
• The company is still burning cash at the operating level. Despite investment gains, Inovio has consistently posted large negative operating cash flow, including $(21.6 million) in Q1 2026.
• The balance sheet is heavily liability-loaded relative to assets. In Q1 2026, total liabilities were $43.7 million versus total assets of $49.8 million, leaving only $6.1 million in common equity.

Looking at the longer trend, Inovio’s balance sheet has gone through major swings. Cash and investments were much higher in late 2024 and 2025, but the company has used a significant amount of that capital to fund operations. The business has also relied repeatedly on stock issuance, which is a common pattern for pre-revenue biotech companies but is unfavorable for existing shareholders.

Bottom line: Inovio still looks like a high-risk, cash-burning biotech story. The company has enough liquidity for now, but without meaningful revenue growth or a major clinical/commercial catalyst, the stock will likely remain driven by financing needs, pipeline news, and dilution risk rather than operating fundamentals.